Skip to contentG
Guided Therapeutics Inc
G
GTHPGuided Therapeutics Inc Q3 2020 · 10-Q
Revenue$77.00K$77.00K+7,600.0% vs Q3 2019 Net Income$1.58M$1.58MN/M vs Q3 2019 EPS Diluted$0.03$0.03N/M vs Q3 2019 Gross Profit$65,000+6,400.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Guided Therapeutics Inc · CIK 924515 · Engraved from SEC EDGAR
Operating Cash Flowderived-$606,000N/M Free Cash Flowderived-$606,000N/M Margins · derivedGross margin84.4%−15.6 pt vs Q3 2019
Operating margin-198.7%+18601.3 pt vs Q3 2019
Net margin2045.5%+14645.5 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 5, 2020 · 36 d after period end